$
43.47
10:08 PM EST
Business Description
Usana Health Sciences Inc
NAICS : 311999
SIC : 2021
ISIN : US90328M1071
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 40.98 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.07 | |||||
Interest Coverage | 355.23 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 7.22 | |||||
Beneish M-Score | -2.47 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -3.7 | |||||
3-Year EBITDA Growth Rate | -12.4 | |||||
3-Year EPS without NRI Growth Rate | -17.4 | |||||
3-Year FCF Growth Rate | -24.8 | |||||
3-Year Book Growth Rate | 7.4 | |||||
Future 3-5Y EPS without NRI Growth Rate | 12 | |||||
Future 3-5Y Total Revenue Growth Rate | 7.45 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 39.68 | |||||
9-Day RSI | 37.75 | |||||
14-Day RSI | 37.92 | |||||
6-1 Month Momentum % | 2.9 | |||||
12-1 Month Momentum % | -30 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.52 | |||||
Quick Ratio | 3 | |||||
Cash Ratio | 2.78 | |||||
Days Inventory | 130.17 | |||||
Days Payable | 20.75 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 3.1 | |||||
Shareholder Yield % | 0.05 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 80.82 | |||||
Operating Margin % | 10.11 | |||||
Net Margin % | 6.93 | |||||
FCF Margin % | 6.1 | |||||
ROE % | 13.71 | |||||
ROA % | 10.5 | |||||
ROIC % | 18.08 | |||||
ROC (Joel Greenblatt) % | 105.83 | |||||
ROCE % | 21.23 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 13.17 | |||||
Forward PE Ratio | 15.7 | |||||
PE Ratio without NRI | 13.17 | |||||
Shiller PE Ratio | 8.96 | |||||
Price-to-Owner-Earnings | 20.54 | |||||
PS Ratio | 0.93 | |||||
PB Ratio | 1.67 | |||||
Price-to-Tangible-Book | 1.85 | |||||
Price-to-Free-Cash-Flow | 14.98 | |||||
Price-to-Operating-Cash-Flow | 11.91 | |||||
EV-to-EBIT | 4.94 | |||||
EV-to-EBITDA | 4.12 | |||||
EV-to-Revenue | 0.55 | |||||
EV-to-Forward-Revenue | 0.57 | |||||
EV-to-FCF | 9.04 | |||||
Price-to-Projected-FCF | 0.57 | |||||
Price-to-Median-PS-Value | 0.57 | |||||
Price-to-Graham-Number | 1.04 | |||||
Price-to-Net-Current-Asset-Value | 2.95 | |||||
Price-to-Net-Cash | 4.27 | |||||
Earnings Yield (Greenblatt) % | 20.24 | |||||
FCF Yield % | 6.71 | |||||
Forward Rate of Return (Yacktman) % | 6.96 |